Basis: Current FMP quote-based enterprise value / four-quarter operating income. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBIT ratio is N/A as of 2026-10-06T19:36:33.330Z.
Calculation as of: 2026-10-06T19:36:33.330Z.
Quote observation: 2026-10-06T19:35:24.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: c1a6838803f42d6ea125a2cca62df7e150df7eb7d5f2d1fff74d5c1a91b3d340
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBIT RATIO
N/A
Market Cap
$485.07M
EV/EBIT Ratio
14.90x
TTM Avg
10.51x
3Y Avg
8.16x
5Y Avg
8.11x
Market Cap
$474.32M
EV/EBIT Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$471.56M
EV/EBIT Ratio
N/A
TTM Avg
5.92x
3Y Avg
17.76x
5Y Avg
17.76x
Market Cap
$469.66M
EV/EBIT Ratio
N/A
TTM Avg
197.32x
3Y Avg
197.32x
5Y Avg
197.32x
Market Cap
$499.60M
EV/EBIT Ratio
12.68x
TTM Avg
18.96x
3Y Avg
18.37x
5Y Avg
48.35x
| NAME | MARKET CAP | EV/EBIT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Evolus, Inc. (EOLS) | $484.69M | N/A | N/A | N/A | N/A |
| Puma Biotechnology, Inc. (PBYI)vs › | $485.07M | 14.90x | 10.51x | 8.16x | 8.11x |
| Oculis Holding AG (OCS)vs › | $490.49M | N/A | N/A | N/A | N/A |
| Bright Minds Biosciences Inc. (DRUG)vs › | $474.32M | N/A | N/A | N/A | N/A |
| Contineum Therapeutics, Inc. (CTNM)vs › | $471.56M | N/A | 5.92x | 17.76x | 17.76x |
| Alpha Teknova, Inc. (TKNO)vs › | $469.66M | N/A | 197.32x | 197.32x | 197.32x |
| Kamada Ltd. (KMDA)vs › | $469.86M | 16.25x | 15.53x | 17.24x | 21.68x |
| Arvinas, Inc. (ARVN)vs › | $470.68M | N/A | N/A | N/A | N/A |
| Tactile Systems Technology, Inc. (TCMD)vs › | $499.60M | 12.68x | 18.96x | 18.37x | 48.35x |
| Cerus Corporation (CERS)vs › | $468.55M | N/A | N/A | N/A | N/A |
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
